“Number needed to treat: enigmatic results for exacerbations in COPD.” Samy Suissa. Eur Respir J 2015; 45: 875–878.


Source: Eur Respir J, 51 (6) 1452165; 10.1183/13993003.52165-2014
Journal Issue: June
Disease area: Airway diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Number needed to treat: enigmatic results for exacerbations in COPD.” Samy Suissa. Eur Respir J 2015; 45: 875–878.. Eur Respir J, 51 (6) 1452165; 10.1183/13993003.52165-2014

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
“Dead space: the physiology of wasted ventilation.” H. Thomas Robertson. Eur Respir J 2015; 45: 1704–1716.
Source: Eur Respir J 2015; 46: 1226
Year: 2015


“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953.
Source: Eur Respir J 2014; 43: 1825
Year: 2014


“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. Eur Respir J 2018; 51: 1702444.
Source: Eur Respir J, 51 (2) 1752444; 10.1183/13993003.52444-2017
Year: 2018


“Lung function race, ethnicity: a conundrum.” Philip H. Quanjer. Eur Respir J 2013; 41: 1249–1251.
Source: Eur Respir J 2013; 42: 1162
Year: 2013


“Do bacteria have a role in asthma development?” J. Armann and E. von Mutius. Eur Respir J 2010; 36: 469–471.
Source: Eur Respir J, 54 (1) 1050414; 10.1183/13993003.50414-2010
Year: 2019


“GINA 2015: the latest iteration of a magnificent journey.” Jean Bousquet and Marc Humbert. Eur Respir J 2015; 46: 579–582.
Source: Eur Respir J 2015; 46: 1854
Year: 2015


“Alveolar macrophages carbon load: a marker of exposure?” Chinedu Nwokoro, Rossa Brugha and Jonathan Grigg. Eur Respir J 2013; 41: 763.
Source: Eur Respir J 2013; 42: 295
Year: 2013


“Bronchodilator combinations for COPD: real hopes or a new Pandora's box?” Nicolas Roche and Pascal Chanez. Eur Respir J 2013; 42: 1441–1445.
Source: Eur Respir J 2014; 43: 658
Year: 2013


“Exercise pulmonary haemodynamics: a test in search of purpose.” J. Gerry Coghlan and Harm Jan Bogaard. Eur Respir J 2016; 47: 1315–1317.
Source: Eur Respir J 2016; 48: 285
Year: 2016


“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057.
Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018
Year: 2018


“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.
Source: Eur Respir Rev 2015; 24: 545
Year: 2015


“Asthma inhaler adherence determinants in adults: systematic review of observational data.” Alexandra L. Dima, Gimena Hernandez, Oriol Cunillera, Montserrat Ferrer, Marijn de Bruin and the ASTRO-LAB group. Eur Respir J 2015; 45: 994–1018.
Source: Eur Respir J 2016; 47:1892
Year: 2016


Eur Respir J 2010; 35: 505–514
Source: Eur Respir J 2010; 36: 1225
Year: 2010


“Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options.” Winfried Randerath, Oana Deleanu, Sophia Schiza and Jean-Louis Pepin. Eur Respir Rev 2019; 28: 190084.
Source: Eur Respir Rev, 28 (154) 195084; 10.1183/16000617.5084-2019
Year: 2019


“Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.” Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown. Eur Respir Rev 2017; 26: 170050.
Source: Eur Respir Rev, 27 (148) 175050; 10.1183/16000617.5050-2017
Year: 2018


“Lung cancer survival in Norway, 1997–2011: from nihilism to optimism.” Yngvar Nilssen, Trond Eirik Strand, Lars Fjellbirkeland, Kristian Bartnes and Bjørn Møller. Eur Respir J 2016; 47: 275–287.
Source: Eur Respir J 2016; 47: 1297
Year: 2016


“The role of nebulised budesonide in the treatment of exacerbations of COPD.” H. Gunen, S.S. Hacievliyagil, O. Yetkin, G. Gulbas, L.C. Mutlu and E. In. Eur Respir J 2007; 29: 660–667.
Source: Eur Respir J 2014; 44: 272
Year: 2014


“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.
Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019
Year: 2020


“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019
Year: 2019


“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022.
Source: Eur Respir Rev, 28 (154) 195022; 10.1183/16000617.5022-2019
Year: 2019